A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Trial Profile

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).
    • 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).
    • 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top